SAKK - a Trial to Evaluate Antitumor Efficacy of Faslodex® After Aromatase Inhibitor Failure in Advanced Breast Cancer

NCT00272740 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

93

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasms

Interventions

DRUG: Fulvestrant

Sponsor

AstraZeneca